Haematologica (Nov 2017)
Mutational status of IGHV is the most reliable prognostic marker in trisomy 12 chronic lymphocytic leukemia
- Pietro Bulian,
- Riccardo Bomben,
- Michele Dal Bo,
- Antonella Zucchetto,
- Francesca Maria Rossi,
- Massimo Degan,
- Federico Pozzo,
- Tamara Bittolo,
- Vanessa Bravin,
- Tiziana D’Agaro,
- Michaela Cerri,
- Annalisa Chiarenza,
- Kari G. Chaffee,
- Adalgisa Condoluci,
- Giovanni D’Arena,
- Michele Spina,
- Francesco Zaja,
- Gabriele Pozzato,
- Francesco Di Raimondo,
- Davide Rossi,
- Giovanni Del Poeta,
- Gianluca Gaidano,
- Tait D. Shanafelt,
- Valter Gattei
Affiliations
- Pietro Bulian
- Clinical and Experimental Onco-Hematology Unit, IRCCS Centro di Riferimento Oncologico, Aviano, Italy
- Riccardo Bomben
- Clinical and Experimental Onco-Hematology Unit, IRCCS Centro di Riferimento Oncologico, Aviano, Italy
- Michele Dal Bo
- Clinical and Experimental Onco-Hematology Unit, IRCCS Centro di Riferimento Oncologico, Aviano, Italy
- Antonella Zucchetto
- Clinical and Experimental Onco-Hematology Unit, IRCCS Centro di Riferimento Oncologico, Aviano, Italy
- Francesca Maria Rossi
- Clinical and Experimental Onco-Hematology Unit, IRCCS Centro di Riferimento Oncologico, Aviano, Italy
- Massimo Degan
- Clinical and Experimental Onco-Hematology Unit, IRCCS Centro di Riferimento Oncologico, Aviano, Italy
- Federico Pozzo
- Clinical and Experimental Onco-Hematology Unit, IRCCS Centro di Riferimento Oncologico, Aviano, Italy
- Tamara Bittolo
- Clinical and Experimental Onco-Hematology Unit, IRCCS Centro di Riferimento Oncologico, Aviano, Italy
- Vanessa Bravin
- Clinical and Experimental Onco-Hematology Unit, IRCCS Centro di Riferimento Oncologico, Aviano, Italy
- Tiziana D’Agaro
- Clinical and Experimental Onco-Hematology Unit, IRCCS Centro di Riferimento Oncologico, Aviano, Italy
- Michaela Cerri
- Division of Hematology – Department of Translational Medicine – Amedeo Avogadro University of Eastern Piedmont, Novara, Italy
- Annalisa Chiarenza
- Division of Hematology, Ferrarotto Hospital, Catania, Italy
- Kari G. Chaffee
- Department of Hematology, Mayo Clinic, Rochester, MN, USA
- Adalgisa Condoluci
- Oncology Institute of Southern Switzerland (IOSI), Bellinzona, Switzerland
- Giovanni D’Arena
- IRCCS, Referral Cancer Center of Basilicata, Potenza, Italy
- Michele Spina
- Oncologia Medica A IRCCS, Centro di Riferimento Oncologico, Aviano, Italy
- Francesco Zaja
- Clinica Ematologica, Centro Trapianti e Terapie Cellulari “Carlo Melzi” DISM, Azienda Ospedaliera Universitaria S. Maria Misericordia, Udine, Italy
- Gabriele Pozzato
- Department of Internal Medicine and Hematology, Maggiore General Hospital, University of Trieste, Italy
- Francesco Di Raimondo
- Division of Hematology, Ferrarotto Hospital, Catania, Italy
- Davide Rossi
- Oncology Institute of Southern Switzerland (IOSI), Bellinzona, Switzerland
- Giovanni Del Poeta
- Division of Hematology, S. Eugenio Hospital and University of Tor Vergata, Rome, Italy
- Gianluca Gaidano
- Division of Hematology – Department of Translational Medicine – Amedeo Avogadro University of Eastern Piedmont, Novara, Italy
- Tait D. Shanafelt
- Department of Hematology, Mayo Clinic, Rochester, MN, USA
- Valter Gattei
- Clinical and Experimental Onco-Hematology Unit, IRCCS Centro di Riferimento Oncologico, Aviano, Italy
- DOI
- https://doi.org/10.3324/haematol.2017.170340
- Journal volume & issue
-
Vol. 102,
no. 11
Abstract
No abstracts available.